NewLink Genetics Corp  

(Public, NASDAQ:NLNK)   Watch this stock  
Find more results for NLNK
14.18
-0.10 (-0.70%)
Feb 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.01 - 14.47
52 week 9.23 - 23.80
Open 14.19
Vol / Avg. 127,794.00/247,624.00
Mkt cap 410.24M
P/E     -
Div/yield     -
EPS -3.23
Shares 29.13M
Beta 1.11
Inst. own 49%
Feb 27, 2017
Q4 2016 NewLink Genetics Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -101.27% -58.95%
Operating margin -109.92% -49.05%
EBITD margin - -46.73%
Return on average assets -34.08% -17.96%
Return on average equity -43.34% -20.57%
Employees 210 -
CDP Score - -

Address

2503 S Loop Dr Ste 5100
AMES, IA 50010-8641
United States - Map
+1-515-2965555 (Phone)
+1-515-2963520 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.

Officers and directors

Charles J. Link Jr. M.D. Chairman of the Board, Chief Executive Officer, Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Nicholas N. Vahanian M.D. President, Chief Medical Officer, Director
Age: 47
Bio & Compensation  - Reuters
John Bell Henneman III Chief Financial Officer, Secretary
Age: 54
Bio & Compensation  - Reuters
Brian Wiley Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Thomas A. Raffin M.D. Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Paolo Pucci Director
Age: 55
Bio & Compensation  - Reuters
Paul R. Edick Independent Director
Age: 61
Bio & Compensation  - Reuters
Joseph B. Saluri Independent Director
Age: 48
Bio & Compensation  - Reuters
Ernest J. Talarico III Independent Director
Age: 44
Bio & Compensation  - Reuters